# Genmab: Phase 2 study closed enrollment, 78 enrolled (Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Genmab |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) |
| NCT ID | NCT04542824 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma |
| Intervention types | biological, drug |
| Target enrollment | 78 |
| Site countries | Japan |
| Posted | 2020-09-09 |
| Planned start | 2020-08-20 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-06 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04542824). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.